Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

Gastric cancer (GC) represents an important contributor to the global burden of cancer,
being one of the most common and deadly malignancies worldwide. According to TCGA and …

Gastric cancer is a major source of global cancer mortality with limited treatment options and
poor patient survival. As our molecular understanding of gastric cancer improves, we are …

Background Clinicopathological and molecular features of responders to nivolumab for
advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC …

Genetic and epigenetic alterations have been under concentrated investigations for many
years in order to unearth the molecules regulating human cancer pathogenesis. However …

PIK3CA mutations in cancer regulate tumour immunogenicity. Given that PIK3CA mutation
subtypes influence therapeutic responses to AKT inhibitor and that H1047R mutation …

Background Gastric cancer is one of the most common malignancies worldwide. Although
the diagnosis and treatment of this disease have substantially improved in recent years, the …

Gastric cancer (GC) is one of the most common lethal malignant neoplasms worldwide, with
limited treatment options for both locally advanced and/or metastatic conditions, resulting in …

Background. Oxidative stress produced a large amount of reactive oxygen species (ROS),
which played a pivotal role in balanced ability and determining cell fate. The activated Nrf2 …

Abstract Purpose Although RAS and PIK3CA mutations have been associated with
resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer, their …